PharmaMar presents eleven scientific publications at the Annual Meeting of the American Association for Cancer Research (AACR)

PharmaMar (MSE:PHM), global leader in research, development and commercialization of marine-derived oncology treatments, is once again participating in the Annual Meeting of the American Association for Cancer Research (AACR), being held in Chicago from April 25th to 30th, 2025. On this occasion, the Company is presenting eleven new studies with results on the activity of its compounds: lurbinectedin (Zepzelca®), ecubectedin, PM54, PM534, and trabectedin (Yondelis®). This reinforces PharmaMar’s ongoing commitment to innovation and cancer research. “We continue to advance the study of the therapeutic potential of marine-derived molecules, both in well-established compounds and in those in earlier stages of development. Our participation this year in the world’s leading oncology research congress reflects our firm commitment to scientific innovation and the path we are building to provide potential therapeutic alternatives for patients,” says Carmen Cuevas, VP of R&D at PharmaMar. The main conclusions from the presented studies highlight the potential of two novel transcription inhibitors, PM54 and ecubectedin as innovative antitumor agents. Ecubectedin has demonstrated encouraging antitumor efficacy in both gastric and neuroendocrine-prostate cancer models. In collaboration with KU Leuven University (Belgium), data also confirm promising antitumor activity of both ecubectedin and PM54 in representative models of soft tissue sarcomas (STS). Additionally, data on PM534 are being presented. PM534 is a novel tubulin-targeting agent, that may bypass the most common resistance mechanisms, limiting the effectiveness of standard microtubule-binding drugs. Finally, the studies also show the antitumor activity of lurbinectedin in NUT carcinoma—a rare type of cancer that forms in the head, neck and lungs. Furthermore, new insights into the mechanism of action of trabectedin will also be shared. The full list of all presentations supported by PharmaMar or its collaborators at the AACR 2025 Annual Meeting is as follows: COMPOUNDTITLELEAD AUTHORABSTRACT Ecubectedin (PM14)Ecubectedin’s role in targeting transcriptional regulators in neuroendocrine prostate cancer.  Laura Almalé, PhD  Location: Section 22 Board Number: 23 Published Abstract Number: 1771 April 28, 2025 Ecubectedin as a promising therapeutic agent against gastric cancer through Wnt/β-Catenin modulation.  Alejandro Losada, PhDLocation: Section 21 Board Number: 8 Published Abstract Number: 5630 April 29, 2025 The novel transcriptional inhibitor ecubectedin demonstrates strong antitumor activity in patent-derived xenograft models of soft tissue sarcoma.Daniël Gorgels, PhDLocation: Section 21 Board Number: 1 Published Abstract Number: 6857 April 30, 2025 PM534Overcoming resistance to tubulin-targeting drugs with PM534: an innovative microtubule-targeting compound.Pablo M. Aviles, PharmD, PhDLocation: Section 21 Board Number: 8 Published Abstract Number: 6864 April 30, 2025 PM54PM54, a novel transcription inhibitor with promising broad spectrum antitumor activity.Marcelo Lima Ribeiro, PhDLocation: Section 22 Board Number: 25 Published Abstract Number: 1773 April 28, 2025 The next generation transcriptional inhibitor PM54 demonstrates strong antitumor activity in patient-derived xenograft models of soft tissue sarcoma.Daniël Gorgels, PhDLocation: Section 21 Board Number: 2 Published Abstract Number: 6858 April 30, 2025 Pan-inhibition of super-enhancer-driven oncogenic transcription by novel synthetic ecteinascidins yields potent anti-cancer activityJulian Obid, PhDLocation: Section 21 Board Number: 13 Published Abstract Number: 1738 April 28, 2025 Trabectedin (Yondelis®)Redefining the Molecular Target for Trabectedin (ET743) as Stable Covalent Bonding to N2 of Guanine in Duplex Stem-Loops of G-Quadruplexes.Laurence H. Hurley, PhD  Location: Section 19 Board Number: 2 Published Abstract Number: 2972 April 28, 2025 Lurbinectedin (Zepzelca®)New therapeutic approaches in NUT Carcinoma: an unmet need.María Virgina Sáchéz-Becerra, PhDLocation: Section 34 Board Number: 23 Published Abstract Number: 5996 April 29, 2025 Lurbinectedin-Induced Transcriptional Reprogramming: A Pathway to Sensitise SCLC to ImmunotherapyJ.S. Russo-Cabrera, PhDLocation: Section 23 Board Number: 13 Published Abstract Number: 5837 April 29, 2025 Lurbinectedin Irinotecan as a new therapeutic combination for Small Cell Lung CancerMiguel Ruiz-Torres, PhDLocation: Section 34 Board Number: 13 Published Abstract Number: 5986 April 29, 2025

The release as fetched from its publisher. pharmamar.com ↗